Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
Curis Lifesciences Ltd. has refiled a Draft Red Herring Prospectus (DRHP) with the exchange on to raise funds through Initial Public Offer (IPO).
The initial submission on December 31, 2024 was withdrawn by the company on May 8, 2025 prompting the company to refile the documents.
Curis Lifesciences Ltd. IPO is a Book Build Issue consisting solely of fresh issue of upto 0.23 crore equity shares.
The equity shares are proposed to be listed on the NSE SME. Swastika Investmart Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Curis Lifesciences IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Issue Price Band | [.] to [.] per share |
| Lot Size | |
| Sale Type | Fresh Capital |
| Total Issue Size | 22,50,000 shares (aggregating up to ₹[.] Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 59,34,434 shares |
| Share Holding Post Issue | 81,84,434 shares |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50% of the Net Issue |
| Retail Shares Offered | Not more than 35% of the Net Issue |
| NII Shares Offered | Not more than 15% of the Net Issue |
| Description | Date |
|---|---|
| Offer document returned | |
| Filed with SEBI/Exchange | Tue, Dec 31, 2024 |
| Offer document withdrawn | Thu, May 8, 2025 |
| Filed with SEBI/Exchange | Fri, Jun 27, 2025 |
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue
Established in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.
The company manufactures pharmaceutical products globally and domestically on a loan license or contract basis, as well as for its own brand marketing.
The company serves over 100 corporate clients on loan licenses or contract manufacturing and 2 clients for its own brand marketing in Yemen and Kenya.
Curis Lifesciences specialises in the development, manufacturing, and distribution of a diverse range of pharmaceutical products, including:
The company operates a state-of-the-art manufacturing facility in Sanand, Gujarat, adhering to stringent quality control measures to ensure product safety and efficacy.
The company offers various pharmaceutical formulations and products manufactured under contract.
They supply tablets, capsules, external preparations, oral liquids, and sterile ophthalmic ointments.
As of June 30th, 2024, the company has 93 permanent employees.
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 50.12 | 33.82 | 29.67 | 27.40 |
| Total Income | 36.91 | 35.89 | 36.39 | 23.76 |
| Profit After Tax | 5.30 | 5.03 | 1.85 | 0.49 |
| EBITDA | 8.89 | 8.41 | 3.25 | 3.58 |
| Net Worth | 15.53 | 5.97 | 0.95 | 0.90 |
| Reserves and Surplus | 9.59 | 5.47 | 0.45 | -1.40 |
| Total Borrowing | 16.16 | 17.09 | 16.19 | 17.62 |
| Amount in ₹ Crore | ||||
| KPI | Values |
|---|---|
| ROE | 145.20% |
| ROCE | 34.89% |
| Debt/Equity | 2.86 |
| RoNW | 84.12% |
| PAT Margin | 14.13% |
| EBITDA Margin | 23.65% |
The Company Curis Lifesciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:
| S.No. | Objects of the Issue | Expected Amount (₹ in crores) |
|---|---|---|
| 1 | Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities | 2.44 |
| 2 | Capital Expenditure towards Construction of a Storage Facility | 3.62 |
| 3 | Pre-payment/Repayment of outstanding Secured Loans | 2.60 |
| 4 | Product Registrations in other countries | 2.61 |
| 5 | Funding our Working Capital Requirements | 11.25 |
| 6 | General Corporate Purposes |
Curis Lifesciences Ltd.
PF-23, GIDC Sanand - II,
Industrial Estate,
Sanand
Ahmedabad, Gujarat, 382110
Phone: +91 99045 22543
Email: cs@curisls.com
Website: https://curisls.com/
MUFG Intime India Pvt.Ltd.
Phone: +91-22-4918 6270
Email: curislifesciences.smeipo@linkintime.co.in
Website: https://linkintime.co.in/Initial_Offer/public-issues.html
Curis Lifesciences IPO is a SME IPO of 22,50,000 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at . The minimum order quantity is .
The Curis Lifesciences IPO open and close dates are not available as of now.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Curis Lifesciences IPO using UPI as a payment gateway. Zerodha customers can apply in Curis Lifesciences IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Curis Lifesciences IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Curis Lifesciences IPO dates are not announced. Please check back again after some time.
Curis Lifesciences IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Curis Lifesciences IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Curis Lifesciences IPO will be done on [.], and the allotted shares will be credited to your demat account by [.]. Check the Curis Lifesciences IPO allotment status.
The Curis Lifesciences IPO listing date is not yet announced. The tentative date of Curis Lifesciences IPO listing is [.].
Useful Articles
